Surrozen focuses on ophthalmology programs, raising $175 million to advance treatments while discontinuing SZN-043 for alcohol-associated hepatitis. Surrozen, Inc. has announced a strategic shift to ...
USPTO Allows Claims Covering Topical Metformin Eye-Drop Therapy for Retinal Degeneration, Including Age-Related Macular DegenerationPalm Beach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results